Clinical research of domestic entecavir treating chronic hepatitis B
Shen Huajiang
Wang Zhiwei
Sun Fang
Yu Yafeng
Ding Feng
Abstract：Objective To investigate the effect of domestic entecavir on chronic hepatitis B.Methods The virology,serology and biochemical indicators of 200 patients who received entecavir for the treatment of chronic hepatitis B were analyzed before treatment and 12,24 and 48 weeks after treatment.Results After 48 weeks of treatment,hepatitis B virus(HBV) DNA negative rate was 84.5％ (169/200) ; hepatitis B e antigen(HBeAg) seroconversion rate was 23.4％ (33/141) ; alanime transaminase (ALT) normolization rate was 78.5％ (157/200)and drug resistant rate was 0.The rate of HBeAg seroconversion in patients with baseline ALT ＞ 5 ULN was significantly higher than tht in patients with 2 to 5 ULN[35.4％ (19/54) vs 16.1％ (14/87),P ＜0.05].Compared with patients with no HBV DNA negative conversion at 24 weeks,ratio of HBV DNA negative conversion,ALT normalization and HBeAg seroconversion were significantly higher in patients with HBV DNA negative 48 weeks after treatment [92.4％ (134/145) vs 63.6％ (35/55),86.2％ (125/145) vs 58.2％ (32/55),20.7％ (30/145) vs 5.5％ (3/55),P ＜ 0.05].The rate of HBeAg sero conversion in patients with G ＞ 2 was significantly higher than that in patients with G ≤2 [37.5％ (12/32) vs 15.0％ (3/20),P ＜ 0.05].No patients stopped treatment due to severe adverse effects.Conclusion Entecavir can inhibit HBV DNA replication,normalize ALT and promote HBeAg seroconversion; with low drug resistance rate.
Keywords：Domestic entecavirChronic hepatitis BEfficacyInfluencing factors
Publication Date：2015-02-28
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 209-213 )